CLINICAL_TRIALS
trial_result
· 2025-05-29
Clinical Trial Update: A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough [Phase 2]
Summary
Phase 2 study evaluating nalbuphine extended-release for cough in idiopathic pulmonary fibrosis has completed and posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Trevi Therapeutics | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2025-05-29